Bispecific mAb(2) Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab

Inhibition of complement activation via the overexpression of complement-regulatory proteins (CRPs), most notably CD46, CD55 and CD59, is an efficient mechanism of disguise of cancer cells from a host immune system. This phenomenon extends to counteract the potency of therapeutic antibodies that cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Stadlbauer, Katharina, Andorfer, Peter, Stadlmayr, Gerhard, Rüker, Florian, Wozniak-Knopp, Gordana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103234/
https://www.ncbi.nlm.nih.gov/pubmed/35563599
http://dx.doi.org/10.3390/ijms23095208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103234/
https://www.ncbi.nlm.nih.gov/pubmed/35563599
http://dx.doi.org/10.3390/ijms23095208

Ejemplares similares